The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Relationship Between Lipid Levels and Clinical Outcomes in the Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) Trial: To What Extent Is the Reduction in Coronary Events With Pravastatin Explained by On-Study Lipid Levels?
Abstract
Background — The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) trial showed that pravastatin significantly reduced mortality and coronary heart disease (CHD) events in 9014 patients with known CHD and total cholesterol 4.0 to 7.0 mmol/L at baseline. Secondary objectives included assessment of CHD event reduction according to lipid levels. Methods and Results — We investigated the relationships of baseline and on-study lipids with subsequent CHD events in separate Cox models. Treatment effect on CHD event reduction was examined by baseline lipids and after adjustment for on-study lipid levels. Baseline lipids were significant predictors of CHD events. The adjusted relative risk per mmol/L (on placebo) was 1.24 ( P =0.004) for total cholesterol, 1.28 ( P =0.002) for low-density lipoprotein cholesterol, and 0.52 ( P =0.004) for high-density lipoprotein cholesterol. Apolipoproteins A1 and B were strong predictors (each P =0.001). Pravastatin reduced the risk of the composite outcome of fatal CHD or nonfatal myocardial infarction by 24% (95% confidence interval [CI], 15% to 32%) and the expanded end point of fatal CHD, nonfatal myocardial infarction, unstable angina, or coronary revascularization by 17% (95% CI, 10% to 24%). Similar relative effects were observed for different categories of baseline lipids. The proportion of treatment effect explained by on-study lipid levels was 67% (95% CI, 27% to 106%) for the composite and 97% (95% CI, 49% to 145%) for the expanded end point. The most important lipids associated with event reduction were apolipoprotein B, low-density lipoprotein cholesterol, and the combination of total and high-density lipoprotein cholesterol. Conclusions — Changes in lipid levels can explain all or most of the observed benefit of pravastatin. Some treatment effect may also be mediated through nonlipid changes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Measurement Error in Nonlinear Models
Carroll, R. J., Ruppert, D., & Stefanski, L. A. (1995) · Springer eBooks · doi:10.1007/978-1-4899-4477-1 · Cited by 1,749
Law, M. R., Wald, N. J., & Thompson, S. G. (1994) · BMJ · doi:10.1136/bmj.308.6925.367 · Cited by 1,210
Antiatherothrombotic Properties of Statins: Implications for Cardiovascular Event Reduction
Rosenson, R. S., & Tangney, C. C. (1998) · JAMA · doi:10.1001/jama.279.20.1643 · Cited by 954
Pekkanen, J., Linn, S., Heiss, G., Suchindran, C. M., Leon, A., Rifkind, B. M., & Tyroler, H. A. (1990) · New England Journal of Medicine · doi:10.1056/nejm199006143222403 · Cited by 821
Cited by
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Prepared by: British Cardiac Society, B. H. S. (2005) · Heart · doi:10.1136/hrt.2005.079988 · Cited by 1,216
Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations
Vasan, R. S. (2006) · Circulation · doi:10.1161/circulationaha.104.482570 · Cited by 1,212
Boekholdt, S. M., Arsenault, B. J., Mora, S., Pedersen, T. R., LaRosa, J. C., Nestel, P. J., Simes, R. J., Durrington, P., Hitman, G. A., Welch, K. M. A., et al. (2012) · JAMA · doi:10.1001/jama.2012.366 · Cited by 795
Self-citationLipoprotein Management in Patients With Cardiometabolic Risk
Brunzell, J. D., Davidson, M., Furberg, C. D., Goldberg, R. B., Howard, B. V., Stein, J. H., & Witztum, J. L. (2008) · Diabetes Care · doi:10.2337/dc08-9018 · Cited by 707
WALLDIUS, G., & JUNGNER, I. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01643.x · Cited by 583
Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events
Boekholdt, S. M., Hovingh, G. K., Mora, S., Arsenault, B. J., Amarenco, P., Pedersen, T. R., LaRosa, J. C., Waters, D. D., DeMicco, D. A., Simes, R. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.02.615 · Cited by 581
Self-citationOtvos, J. D., Collins, D., Freedman, D. S., Shalaurova, I., Schaefer, E. J., McNamara, J. R., Bloomfield, H. E., & Robins, S. J. (2006) · Circulation · doi:10.1161/circulationaha.105.565135 · Cited by 547
Lipoprotein Management in Patients With Cardiometabolic Risk
Brunzell, J. D., Davidson, M., Furberg, C. D., Goldberg, R. B., Howard, B. V., Stein, J. H., & Witztum, J. L. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.02.034 · Cited by 529
Inflammation, Immunity, and HMG-CoA Reductase Inhibitors: Statins as Antiinflammatory Agents?
Schönbeck, U., & Libby, P. (2004) · Circulation · doi:10.1161/01.cir.0000129505.34151.23 · Cited by 498
Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment
Kastelein, J. J. P., van der Steeg, W. A., Holme, I., Gaffney, M., Cater, N. B., Barter, P., Deedwania, P., Olsson, A. G., Boekholdt, S. M., Demicco, D. A., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.713438 · Cited by 478
Fruchart, J.-C., Sacks, F., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.10.002 · Cited by 463
BARTER, P. J., BALLANTYNE, C. M., CARMENA, R., CABEZAS, M. C., CHAPMAN, M. J., COUTURE, P., DE GRAAF, J., DURRINGTON, P. N., FAERGEMAN, O., FROHLICH, J., et al. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01616.x · Cited by 464
Self-citationApolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment
Sniderman, A., Furberg, C., Keech, A., van Lennep, J. R., Frohlich, J., Jungner, I., & Walldius, G. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12663-3 · Cited by 457
Self-citationContois, J. H., McConnell, J. P., Sethi, A. A., Csako, G., Devaraj, S., Hoefner, D. M., & Warnick, G. R. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.118356 · Cited by 326
Ali, K. M., Wonnerth, A., Huber, K., & Wojta, J. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02081.x · Cited by 292
The Role of Statins in Cancer Therapy
Hindler, K., Cleeland, C. S., Rivera, E., & Collard, C. D. (2006) · The Oncologist · doi:10.1634/theoncologist.11-3-306 · Cited by 291
Current overview of statin-induced myopathy
Rosenson, R. S. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.10.033 · Cited by 287
De Backer, G., Ambrosioni, E., Broch-Johnsen, K., Brotons, C., Cifkova, R., Dallongeville, J., Ebrahim, S., Faergeman, O., Graham, I., Mancia, G., et al. (2003) · European Journal of Cardiovascular Prevention and Rehabilitation · doi:10.1097/00149831-200312001-00001 · Cited by 274
Davidson, M. H., Ballantyne, C. M., Jacobson, T. A., Bittner, V. A., Braun, L. T., Brown, A. S., Brown, W. V., Cromwell, W. C., Goldberg, R. B., McKenney, J. M., et al. (2011) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.07.005 · Cited by 262
Fruchart, J.-C., Sacks, F. M., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.046 · Cited by 260
Black, D. M., Bauer, D. C., Vittinghoff, E., Lui, L.-Y., Grauer, A., Marin, F., Khosla, S., de Papp, A., Mitlak, B., Cauley, J. A., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30159-5 · Cited by 228
Thanassoulis, G., Williams, K., Ye, K., Brook, R., Couture, P., Lawler, P. R., de Graaf, J., Furberg, C. D., & Sniderman, A. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.113.000759 · Cited by 148
Robinson (2012) · doi:10.1016/j.amjcard.2012.07.007 · Cited by 137
Apolipoproteins as markers and managers of coronary risk
Chan, D. C. (2006) · QJM · doi:10.1093/qjmed/hcl027 · Cited by 117
Holme, I., Aastveit, A. H., Jungner, I., & Walldius, G. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.01925.x · Cited by 106
A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias.
de Graaf, J., Couture, P., & Sniderman, A. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0982 · Cited by 80
Evidence for changing lipid management strategy to focus on non-high density lipoprotein cholesterol
Su, X., Kong, Y., & Peng, D. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1080-x · Cited by 72
Low density lipoprotein cholesterol, statins and cardiovascular events: a meta-analysis
Genser, B., & März, W. (2006) · Clinical Research in Cardiology · doi:10.1007/s00392-006-0403-x · Cited by 68
Uchiyama, S., Nakaya, N., Mizuno, K., Ohashi, Y., Tajima, N., Kushiro, T., Teramoto, T., & Nakamura, H. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.04.002 · Cited by 32
van den Bogaard, B., van den Born, B.-J. H., Fayyad, R., Waters, D. D., DeMicco, D. A., LaRosa, J. C., Kastelein, J. J. P., Holme, I., & On behalf of the Treating to New Targets investigators (2011) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02387.x · Cited by 12
Daida, H., Teramoto, T., Kitagawa, Y., Matsushita, Y., Sugihara, M., & APPROACH-J Study Group (2014) · International Heart Journal · doi:10.1536/ihj.13-002 · Cited by 12
Metadata
- Authors
- Simes, R. J., Marschner, I. C., Hunt, D., Colquhoun, D., Sullivan, D., Stewart, R. A. H., Hague, W., Keech, A., Thompson, P., White, H., Shaw, J., & Tonkin, A.
- Venue
- Circulation
- Published
- 2002-03-12
- Volume
- 105
- Issue
- 10
- Pages
- 1162-1169
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2097426078
- Cited by
- 254
- References
- 21
- FWCI
- 17.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.